Literature DB >> 1683422

Production of interleukin-1-receptor antagonist during experimental endotoxaemia.

E V Granowitz1, A A Santos, D D Poutsiaka, J G Cannon, D W Wilmore, S M Wolff, C A Dinarello.   

Abstract

Interleukin-1 (IL-1) has been implicated in the pathogenesis of sepsis. IL-1-receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 activity that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We induced endotoxaemia in 9 healthy human volunteers by injection of Escherichia coli endotoxin, and measured plasma concentrations of IL-1 and IL-1ra by radioimmunoassay during the next 24 h. Peak plasma concentrations of IL-1ra were about a hundred-fold greater than those of IL-1 beta. No IL-1 or IL-1ra were detectable in the plasma of 4 volunteers injected with saline. Our results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683422     DOI: 10.1016/0140-6736(91)92725-h

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  50 in total

Review 1.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis.

Authors:  F Arnalich; E Garcia-Palomero; J López; M Jiménez; R Madero; J Renart; J J Vázquez; C Montiel
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

3.  Immune function and HPA axis activity in free-ranging rhesus macaques.

Authors:  Christy L Hoffman; James P Higham; Michael Heistermann; Christopher L Coe; Brian J Prendergast; Dario Maestripieri
Journal:  Physiol Behav       Date:  2011-05-27

4.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

Review 5.  Understanding rheumatic fever.

Authors:  Pedro Ming Azevedo; Rosa Rodrigues Pereira; Luiza Guilherme
Journal:  Rheumatol Int       Date:  2011-09-28       Impact factor: 2.631

Review 6.  Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.

Authors:  Razi Khan; Eric Rheaume; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2018-09-15       Impact factor: 5.113

7.  Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor.

Authors:  Yujuan Zhang; Saloni Gupta; Alexandra Ilstad-Minnihan; Sashi Ayyangar; Arielle D Hay; Virginia Pascual; Norman T Ilowite; Claudia Macaubas; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2018-06-19       Impact factor: 3.969

8.  In-vivo extravasation induces the expression of interleukin 1 receptor type 1 in human neutrophils.

Authors:  J M Paulsson; A Moshfegh; E Dadfar; C Held; S H Jacobson; J Lundahl
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

9.  Glomerular expression of interleukin-1 receptor antagonist and interleukin-1 beta genes in antibody-mediated glomerulonephritis.

Authors:  F W Tam; J Smith; S J Cashman; Y Wang; E M Thompson; A J Rees
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 10.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.